Open Enrollment for Phase 1 Trial Testing CS1-CAR T-Cell Therapy for Hard-to-Treat Myeloma
A Phase 1 clinical trial is recruiting patients with…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Oncopeptides Prepares NDA for Accelerated Approval of Ygalo as Treatment for Refractory Multiple Myeloma
Oncopeptides is preparing to submit a…
Revlimid Becomes Option for First-line Multiple Myeloma Treatment in England
The National Institute for Health and Care Excellence…
Therapy for Heavily Treated Multiple Myeloma Gets Fast Track Status from FDA
Cellectar Biosciences’ candidate CLR 131 received Fast…
Revlimid and Imnovid Triple Combos Approved in EU for Adults with Multiple Myeloma
The European Commission has approved two combination therapies…
Takeda Oncology Launches Myeloma Patient and Caregiver Mentorship Support Program
Takeda Oncology has launched a mentorship program aimed…
